A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Niharika B MettuSusanna V UlahannanJohanna C BendellIgnacio Garrido-LagunaJohn H StricklerKathleen M MooreRobert StaggAnn M KapounLeonardo FaoroSunil SharmaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Etigilimab had an acceptable safety profile with preliminary evidence of clinical benefit alone and in combination with nivolumab and warrants further investigation in clinical trials.